The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) ...

BD (NYSE: BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system.

Becton, Dickinson settles with SEC for $175M over misleading investors on software flaws in Alaris pumps. Read more here.

BD will pay a civil penalty to resolve charges it misled investors about risks associated with sales of its Alaris infusion pump, the Securities and Exchange Commission said.

Fresenius Kabi is asking hospitals to remove certain pumps because of the risk of an alarm that could interrupt treatment.

Symbiq raises the bar for infusion pump technology with an innovative and user-centric approach. With its unique combination of nurse-friendly features, auto-default to safety software ...

The SEC reached a settlement with Becton Dickinson over allegations of misleading investors regarding risks tied to its Alaris infusion pump. The company agreed to a $175 million civil penalty without ...

The FDA said Fresenius Kabi told customers to remove its Ivenix large-volume infusion pumps from use for repair.

Becton, Dickinson and Co. (BDX) or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S.

Some of the key market players operating in the implantable infusion pump market include Medtronic, Flowonix Medical, Intera Oncology, Tandem Diabetes Care, United Therapeutics, ICU Medical, Johnson & ...